talimogene laherparepvec: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
talimogene laherparepvec: clinical details
Prescribing considerations
- Initiate and supervise through a clinician experienced in cancer care.
- Confirm disease distribution matches the licensed melanoma population and suitable lesions can be injected.
- Assess immune status, immunosuppressive treatment, previous herpes infection, autoimmune disease and history of multiple myeloma.
- Consider airway-compression risk when injecting neck lesions.
- Provide the Patient Alert Card and counsel patients and close contacts about dressings, accidental exposure and viral transmission.
- Record product name and batch number for traceability.
Contraindications and cautions
- Hypersensitivity to talimogene laherparepvec or an excipient
- Severe congenital or acquired cellular and/or humoral immunodeficiency
Monitoring
- Inspect injection sites for necrosis, ulceration, delayed healing, cellulitis and bacterial infection.
- Assess new mucocutaneous, ocular, neurological or systemic symptoms for possible herpetic infection or viral dissemination.
- Monitor for immune-mediated events, including pneumonitis, vasculitis, glomerulonephritis and worsening psoriasis.
- Monitor neck lesions for signs of airway obstruction.
- Review new or enlarging lesions in context because apparent progression can precede response.
Clinical pharmacology
A replication-competent HSV-1 modified by deletion of ICP34.5 and ICP47 and insertion of the human GM-CSF sequence. It combines tumour-selective viral replication and cell lysis with tumour-antigen release and immune stimulation. Clearance occurs through host defences and endogenous protein and DNA degradation, although latent viral DNA cannot be excluded.
Formulation and product differences
- Preservative-free, single-use intralesional solution supplied in two concentrations: 10^6 PFU/mL and 10^8 PFU/mL.
- Vial caps are light green for 10^6 PFU/mL and royal blue for 10^8 PFU/mL.
- The frozen product requires specialist storage, thawing, handling and disposal as a genetically modified organism. It must not be shaken, mixed with other medicines or refrozen after thawing.
talimogene laherparepvec interactions
Formal interaction studies have not been conducted. The main recognised interaction is with anti-herpes treatment.
Acyclovir and other anti-herpes antiviral medicines
Systemic use, or topical use directly at an injection site, may reduce viral activity and interfere with effectiveness. The cancer team should assess benefits and risks.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.